Albany Molecular Research (Albany Molecular Research) EBIT per Share : $-0.34 (TTM As of Jun. 2017)

View and export this data going back to 1999. Start your Free Trial

What is Albany Molecular Research EBIT per Share?

Albany Molecular Research's EBIT per Share for the three months ended in Jun. 2017 was $-0.04. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2017 was $-0.34.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Albany Molecular Research's EBIT per Share or its related term are showing as below:

AMRI's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Albany Molecular Research's EBIT for the three months ended in Jun. 2017 was $-1.6 Mil.

Albany Molecular Research EBIT per Share Historical Data

The historical data trend for Albany Molecular Research's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albany Molecular Research EBIT per Share Chart

Albany Molecular Research Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

EBIT per Share

Get a 7-Day Free Trial

0.02

0.67

0.18

0.41

-0.49

Albany Molecular Research Quarterly Data
	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
EBIT per Share	Get a 7-Day Free Trial															0.19	-0.39	0.04	0.05	-0.04

Albany Molecular Research EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Albany Molecular Research's EBIT per Share for the fiscal year that ended in Dec. 2016 is calculated as

	EBIT per Share		(A: Dec. 2016 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-18.759	/	38.304
=	-0.49

Albany Molecular Research's EBIT per Share for the quarter that ended in Jun. 2017 is calculated as

	EBIT per Share		(Q: Jun. 2017 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.556	/	42.520
=	-0.04

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.34

Albany Molecular Research (NAS:AMRI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Albany Molecular Research EBIT per Share Related Terms

Thank you for viewing the detailed overview of Albany Molecular Research's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Albany Molecular Research (Albany Molecular Research) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albany Molecular Research Inc (NAS:AMRI) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.amriglobal.com

Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.

Executives

Anthony J Maddaluna	director	PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
Felicia I Ladin	officer: SVP, Treasurer & CFO	26 CORPORATE CIRCLE, ALBANY NY 12203
David H Deming	director	C/O BETTER FOR YOU WELLNESS, INC., 1349 EAST BROAD ST, COLUMBUS OH 43205
William S Marth	director, officer: President and CEO	236 GROVE STREET, WELLESLEY MA 02482
Lori M. Henderson	officer: SVP, Secretary & Gen Counsel	MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Una S Ryan	director	329 HAMMOND STREET, CHESTNUT HILL MA 02467
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Gabriel Leung	director	C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Michael A Luther	officer: Senior VP, Discovery Services	21 CORPORATE CIRCLE, ALBANY NY 12203
Mark T Frost	officer: Chief Financial Officer	21 CORPORATE CIRCLE, PO BOX 15098, ALBANY NY 12033-5098
David P Waldek	officer: Chief Financial Officer	ALBANY MOLECULAR RESEARCH INC, 21 CORPORATE CIRCLE PO BOX 15098, ALBANY NY 12212-5098

Albany Molecular Research (Albany Molecular Research) Headlines

No Headlines